Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Top Cited Papers
Open Access
- 1 April 2007
- journal article
- Published by Elsevier in Journal of Lipid Research
- Vol. 48 (4) , 763-767
- https://doi.org/10.1194/jlr.c600025-jlr200
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Aberrant Hepatic Expression of PPARγ2 Stimulates Hepatic Lipogenesis in a Mouse Model of Obesity, Insulin Resistance, Dyslipidemia, and Hepatic SteatosisJournal of Biological Chemistry, 2006
- Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein BCirculation, 2006
- The Nine Lives of ACAT InhibitorsArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Protease Variants, LDL, and Coronary Heart DiseaseNew England Journal of Medicine, 2006
- A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein CholesterolAmerican Journal of Human Genetics, 2006
- An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosisJournal of Lipid Research, 2005
- Tissue Disposition of 2′‐O‐(2‐methoxy) ethyl Modified Antisense Oligonucleotides in MonkeysJournal of Pharmaceutical Sciences, 2004
- Eliminating Atherogenesis in Mice by Switching Off Hepatic Lipoprotein SecretionCirculation, 2003
- PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic miceProceedings of the National Academy of Sciences, 2002
- Toxicity of Antisense OligonucleotidesPublished by Taylor & Francis ,2001